On Friday, Nielsen Holdings PLC (NYSE:NLSN)’s shares declined -1.21% to $44.96.
Nielsen N.V. (NLSN) declared second quarter 2015 results. Revenues were $1,559 million for the second quarter of 2015, down 2.2% due to the impact of foreign exchange, but up 4.8% on a constant currency basis, contrast to the second quarter of 2014.
Adjusted EBITDA for the second quarter raised 1.7% to $468 million, or 7.3% on a constant currency basis contrast to the second quarter of 2014. As a percentage of revenues, adjusted EBITDA grew 116 basis points, or 72 basis points on a constant currency basis, due to the accretive impact of our investments in coverage and analytics capabilities and the benefit of our ongoing productivity initiatives.
Income from ongoing operations for the second quarter raised 52.6% to $116 million, an enhance of 103.5% on a constant currency basis, contrast to the second quarter of 2014. The year over year enhance is largely driven by fees associated with refinancing during the second quarter of 2014, which were not incurred in the second quarter of 2015, and the benefit of ongoing productivity initiatives. Income from ongoing operations per share, on a diluted basis, was $0.31 contrast to $0.19 in the second quarter of 2014.
Nielsen N.V. operates as an information and measurement company. The company provides media and marketing information, analytics, and manufacturer and retailer expertise about what and where consumers buy, read, watch and listen. Its Buy segment provides data on retail measurement services, such as market share and competitive sales volumes; insights into distribution, pricing, merchandising, and promotion; consumer panel measurement, which offers insight into shopper behavior and customer segmentation; and consumer intelligence and analytical services for decision making in development and marketing cycles.
Cadence Design Systems Inc (NASDAQ:CDNS)’s shares dropped -1.12% to $20.29.
Cadence Design Systems Inc (CDNS) and Applied Materials, Inc. (AMAT) recently declared the companies are collaborating on a development program to optimize the chemical-mechanical planarization (CMP) process through silicon characterization and modeling for advanced-node designs at 14 nanometer (nm) and below. The program allows design teams to predict the impact of CMP on both functional yield and parametric yield, and for manufacturing teams to boost planarization performance, which is increasingly critical for advanced FinFET architectures.
The Cadence® and Applied Materials joint development program is focused on front end-of-line (FEOL) and wafer-level CMP modeling. Applied Materials can use the Cadence CMP Process Optimizer, a tool that allows silicon calibration of semi-physical models and optimization of CMP material and process parameters such as pressure, polish time and overall CMP uniformity, to enhance the precision performance of its Reflexion® LK Prime™ CMP system.
Cadence Design Systems, Inc. develops, sells, leases, and licenses electronic design automation (EDA) software, emulation and prototyping hardware, verification intellectual property (VIP), and design intellectual property (design IP) for semiconductor and electronics systems industries worldwide.
At the end of Friday’s trade, Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)‘s shares dipped -1.41% to $6.28.
Spectrum Pharmaceuticals ( SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, recently declared that an overview of the Company’s business strategy and commercial and development-stage programs will be given at the Rodman & Renshaw 17th Annual Global Investment Conference being held at the St. Regis Hotel in New York City. The Company presentation is on Thursday, September 10, 2015, at 9:35 AM ET.
Spectrum Pharmaceuticals, Inc., a biotechnology company, develops and commercializes oncology and hematology drug products. The company markets five drug products, counting FUSILEV for the treatment of patients with metastatic colorectal cancer, rescue after high-dose
impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL); ZEVALIN injection for patients with follicular non-Hodgkins lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation of the anticancer drug vincristine for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; and BELEODAQ injection for patients with relapsed or refractory PTCL. It is also developing Captisol-enabled MELPHALAN, an intravenous formulation for clinicians and patients in the multiple myeloma transplant setting; APAZIQUONE to treat non-muscle invasive bladder cancer; and SPI-2012 for the treatment of chemotherapy-induced neutropenia. The company sells its drugs through a direct sales force in the United States; and through distributors in Europe and Japan.
Teladoc Inc (NYSE:TDOC), ended its Friday’s trading session with -7.10% loss, and closed at $20.82.
CVS Health (CVS) declared that it is working with three proven telehealth companies – American Well, Doctor On Demand and Teladoc (TDOC) – to explore how direct-to-consumer telehealth providers, retail pharmacy and retail clinic providers can collaborate to improve patient care. This represents an expansion of CVS Health’s existing telehealth approach.
This declarement is part of CVS Health’s broader commitment to connected health, exploring new and effective ways that digital technology can improve the health care experience. “A key pillar of our strategy is forging the right partnerships within the industry,” said Brian Tilzer, senior vice president and chief digital officer, CVS Health. “We recognize that some of the best ideas are already being developed, so we’re committed to partnering with other companies to explore and expand on these ideas together.”
Teladoc, Inc. provides telehealth services via mobile devices, the Internet, video, and phone to clients and their customers in the United States. Its solution connects consumers with its physicians and behavioral health professionals who treat a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection, and sinusitis to dermatological conditions, anxiety, and smoking cessation. The company was founded in 2002 and is based in Dallas, Texas.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
